June 03, 2022
During the opening press conference, Endocrinology Network got perspective from a trio of American Diabetes Association executives on the prospect of tirzepatide as an agent for combatting both diabetes and obesity.
May 31, 2022
The American Diabetes Association released updates to their Standards of Care to reflect new data regarding the cardiovascular and renal benefits of agents, including finerenone and SGLT2 inhibitors.
May 17, 2022
Diabetic ketoacidosis increased the likelihood of in-hospital mortality by 61%, the likelihood of major adverse cardiovascular events by 56%, and a likelihood of 30-day readmission by 12% among patients hospitalized with heart failure in the US.
May 13, 2022
A systematic review and meta-analysis from AACE 2022 provides an overview of the potential associations between thyroid dysfunction, including both hypothyroidism and hyperthyroidism, and risk of Parkinson disease.
May 12, 2022
Data presented at AACE 2022 detail levoketoconazole-specific effects observed among patients with endogenous Cushing's syndrome from the phase 3 LOGICS trial.
October 08, 2021
An analysis of nearly 400 patients suggests undergoing thyroid radiofrequency ablation in ambulatory settings was associated with increased risk of intraoperative, postoperative, and perioperative side effects than those performed in operating room settings.
October 07, 2021
An analysis of more than 1.2 million patients who experienced a fracture from 1997-2017 provides insight into contemporary trends in fracture incidence rates based on presence of diabetes.
October 07, 2021
An analysis of more than 650 thyroid eye disease patients is providing clinicians with insight into the most common comorbidities and risk factors associated with increased disease severity in patients with TED.
October 06, 2021
A phase 2 trial presented at ASBMR provides insight into the effects of oral PTH tablets on bone health among postmenopausal women with osteoporosis.
October 06, 2021
An analysis of data from OPTIC and OPTIC-X provide insight into the effects of teprotumumab in longer duration thyroid eye disease and among patients who were nonresponders in the original trial.